Arcutis Biotherapeutics (ARQT)
(Delayed Data from NSDQ)
$8.00 USD
-0.60 (-6.98%)
Updated May 3, 2024 04:00 PM ET
After-Market: $7.99 -0.01 (-0.13%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
ARQT 8.00 -0.60(-6.98%)
Will ARQT be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ARQT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ARQT
Is AdaptHealth (AHCO) Stock Outpacing Its Medical Peers This Year?
Are Medical Stocks Lagging AdaptHealth (AHCO) This Year?
ARQT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Arcutis Biotherapeutics, Inc. (ARQT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year?
Wall Street Analysts See a 54.78% Upside in Arcutis Biotherapeutics, Inc. (ARQT): Can the Stock Really Move This High?
Other News for ARQT
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Biotherapeutics: Betting Big On Zoryve
Buy Rating Reiterated for ARQT Amidst Strong Zoryve Performance and Market Resilience
Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
Analysts Conflicted on These Healthcare Names: Terns Pharmaceuticals (TERN), Abbott Labs (ABT) and Arcutis Biotherapeutics (ARQT)